Second Edition of User’s Guide for Patient Registry Development Published by Agency for Healthcare Research and Quality
Outcome Sciences,
Inc. today announced that the
Agency for Healthcare Research and Quality
(AHRQ) has published the second edition of, “Registries for Evaluating Patient Outcomes: A User’s Guide,” a Federal publication that provides information on designing, implementing, and evaluating patient registries.
The second edition of the User’s Guide, which reflects the work of more than 80 contributors from government, academic and private sectors, includes:
* New methodological developments;
* Emerging topics in registry science, including updates on safety;
* Technological advances; and
* Operational examples and case studies from around the world.
Updates to the original 11 chapters from the 2007 version of the handbook are included, as well as four new sections:
* Use of Registries in Product Safety Assessment
* Planning for the End of a Patient Registry
* Interfacing Registries and EHRs
* Linking Registry Data
OUTCOME was selected by AHRQ in 2005 to lead the effort to create the patient registries guide. OUTCOME’s Drs. Richard Gliklich and Nancy Dreyer served as the guide’s senior editors and authors for several chapters. The second edition includes 38 case studies, which illustrate real-life challenges in the design and conduct of registries. Contributors came from industry, academia, and government, with representation from various agencies in the U.S., as well as the National Institute for Health and Clinical Excellence in the U.K. The work was performed under contract to OUTCOME through its role as an AHRQ DEcIDE Research Center, a component of AHRQ’s Effective Health Care Program.
The guide will be available in on AHRQ’s website (
www.effectivehealthcare.ahrq.gov
) and will also be available in print.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
